| B-cell-depleting therapy in systemic lupus erythematosus. | |
| | |
MedLine Citation:
|
PMID: 22444096 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The emergence of a new class of agents (B-cell-depleting therapies) has opened a new era in the therapeutic approach to systemic lupus erythematosus, with belimumab being the first drug licensed for use in systemic lupus erythematosus in more than 50 years. Four agents deserve specific mention: rituximab, ocrelizumab, epratuzumab, and belimumab. Controlled trials have shown negative results for rituximab, promising results for epratuzumab, and positive results for belimumab. Despite these negative results, rituximab is the most-used agent in patients who do not respond or are intolerant to standard therapy and those with life-threatening presentations. B-cell-depleting agents should not be used in patients with mild disease and should be tailored according to individual patient characteristics, including ethnicity, organ involvement, and the immunological profile. Forthcoming studies of B-cell-directed strategies, particularly data from investigations of off-label rituximab use and postmarketing studies of belimumab, will provide new insights into the utility of these treatments in the routine management of patients with systemic lupus erythematosus. |
| | |
Authors:
|
Manuel Ramos-Casals; Iñaki Sanz; Xavier Bosch; John H Stone; Munther A Khamashta |
Related Documents
:
|
1718706 - Serial eeg in alzheimer's disease: 3 year follow-up and clinical outcome. 14676056 - Comparison of the short test of mental status and the mini-mental state examination in ... 22434306 - Antiphospholipid antibody-related bell's palsy in young women. 15021866 - Valproate use in neuropsychiatric disorders in the elderly. 16641656 - Racial differences in impact of coverage on diabetes self-monitoring in a health mainte... 16594246 - The prevalence of psychiatric disorder and the wish to hasten death among terminally il... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of medicine Volume: 125 ISSN: 1555-7162 ISO Abbreviation: Am. J. Med. Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-03-26 Completed Date: 2012-05-14 Revised Date: 2013-05-21 |
Medline Journal Info:
|
Nlm Unique ID: 0267200 Medline TA: Am J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 327-36 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2012 Elsevier Inc. All rights reserved. |
Affiliation:
|
Laboratory of Autoimmune Diseases Josep Font, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Antibodies, Monoclonal, Humanized / therapeutic use Antibodies, Monoclonal, Murine-Derived / therapeutic use B-Lymphocytes / immunology* Humans Lupus Erythematosus, Systemic / drug therapy*, immunology Randomized Controlled Trials as Topic |
| Grant Support | |
ID/Acronym/Agency:
|
R37 AI049660/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/epratuzumab; 0/ocrelizumab; 0/rituximab; 73B0K5S26A/belimumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of fish oil on ruminal biohydrogenation of C18 unsaturated fatty acids in steers fed grass or...
Next Document: Digitalis toxicity: a fading but crucial complication to recognize.